arrow
R

Robert M. Mader

f creta gmbh, langeck im burgenland, austriahttps://orcid.org/0000-0003-3017-8240view further author information
H指数:41
被引数:5,393

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil

巴西流行地区12个月、双盲、随机、安慰剂对照的III期试验中,一种减毒活疫苗的登革热病毒疫苗在青少年中的安全性和免疫原性的最终结果

2025-12-080
PRE
Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody

临床前B细胞耗竭及经脑穿梭的结晶片段沉默CD20抗体的安全性特征

2025-03-210
OAAI
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults

一项随机,双盲的3期研究,以证明批次间的一致性,并确认减毒活基孔肯雅病毒疫苗候选疫苗VLA1553在健康成人中的免疫原性和安全性

2023-12-1311
OAAI
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
LANCET
IF88.5
2023-06-0158
OAAI
Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo

释放奥沙利铂的铂 (iv) 前药的白蛋白靶向由于体内内吞药物吸收而导致显着的抗癌活性

2021-01-0125
OAAI
Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI

治疗难治性实体瘤的靶向治疗建议-来自真实世界精准医学平台MONDTI的数据

2020-10-237
OAAI